<DOC>
	<DOCNO>NCT02257697</DOCNO>
	<brief_summary>To demonstrate treatment effect refractory nephrotic syndrome MZR non-inferior standard therapy CTX analyze overall remission rate treatment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Mizoribine Treatment Refractory Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bredinin</mesh_term>
	<criteria>Patients medical history clear documentation diagnosis nephrotic syndrome Patient receive renal biopsy within 1 year prior screen confirm pathologic classification : Minimal Change Disease ( MCD ) , IgA nephropathy , Mesangioproliferative Glomerulonephritis ( MsPGN ) , Membranous Nephropathy ( MN ) , Focal Segmental Glomerulosclerosis ( FSGS ) Patient different pathologic classification receive adequate hormone therapy 8 week ( include FSGS 12 week ) prior screen 24hrurine protein≥2.0g/day screen Adequate hormone dose define prednisone ( prednisolone ) equivalent dose 0.8 1.0 mg/kg/day ( inclusive ) Male female patient 18 70 year ( inclusive ) inform consent obtain date Patient body weight 40kg 80kg ( inclusive ) screen Patients sign inform consent form Other primary nephrotic syndrome , e.g . membranoproliferative glomerulonephritis ( MPGN ) Secondary nephrotic syndrome ( e.g . diabetic nephropathy , anaphylactic purpura nephritis , lupus nephritis , type B hepatitisrelated nephritis , renal amyloidosis ) Patient history allergy investigational product ( MZR , CTX ) hormone Patient receive accumulated dosage CTX &gt; 3g within one year prior screen Patient receive immunosuppressant Chinese traditional medicine immunosuppressive effect within 30 day prior screen Patient receive investigational drug within 30 day prior screen Patient receive plasma exchange therapy immunoadsorption therapy within 30 day prior screen Patient require pentostatin live vaccine ( include flu vaccine ) Patient undergo renal replacement therapy Patient receive kidney transplantation Patient malignancy Patient severe hypertension ( SBP &gt; 160mmHg DBP &gt; 100mmHg ) effectively control Patient white blood cell count &lt; 3×109/L /L ( =3.0 GI/L ) Patient SCr &gt; 176.8μmol/L Patient value &gt; 3 time upper limit normal range AST ALT Patient hepatitis B , hepatitis C HIV infection Patient serious infection Patient unsuitable participate study opinion investigator ( e.g . uncontrolled diabetes , central nervous system lupus , lupus encephalopathy , active psychosis , osteonecrosis femoral head , fulminant hepatitis , peptic ulcer , etc . ) Female patient pregnant , currently breast feed willing become pregnant Patient disease would affect evaluation efficacy safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>